trending Market Intelligence /marketintelligence/en/news-insights/trending/eobe24ez8pao3ypwkdjd9w2 content esgSubNav
In This List

Supernus wins patent infringement ruling against TWi regarding epilepsy drug

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Supernus wins patent infringement ruling against TWi regarding epilepsy drug

Supernus Pharmaceuticals Inc. said a U.S. appeals court upheld a previous patent infringement ruling against TWi Pharmaceuticals Inc. regarding its epilepsy drug.

The U.S. Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's decision that TWi infringed on three Supernus patents related to anti-epileptic drug Oxtellar XR.

The appeals court said the three patents are valid. The decision ends all outstanding litigations and generic challenges to Oxtellar XR.

Rockville, Md.-based Supernus previously won a similar appeals decision against Teva Pharmaceutical Industries Ltd's Actavis.

Supernus said it plans to expand Oxtellar XR's indication to include use as a single therapy for partial seizures of epilepsy as well as the development program for bipolar disorder.

The company holds eight issued patents for Oxtellar XR which will expire in 2027 at the earliest.